Lastly, as discussed in this review, PI3K/mTOR/AKT inhibitors and telomerase inhibitors have also shown much potential, and further studies are warranted to explore this treatment option for primary myelofibrosis. The gene discussed is MTOR; the disease is myelofibrosis.